ReviewMedical oncology (Northwood, London, England)2025
Graphene quantum dot-integrated nanocomposites: a promising avenue for glioblastoma treatment.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) remains one of the most aggressive and resistant to treatment types of brain cancer; hence, new therapeutic approaches are required. Recent advances in nanomedicine have positioned graphene quantum dots (GQDs) as promising candidates for targeted cancer therapy due to their exceptional physicochemical properties, biocompatibility, and multifunctional capabilities. This review examines how GQDs can be included in multifunctional nanocomposites and how they might be used to diagnose and treat GBM. We discuss the unique structural and optical characteristics of GQDs that facilitate blood-brain barrier penetration, targeted drug delivery, bioimaging, and photothermal/photodynamic therapy. The design techniques of GQD-based nanocomposites are emphasized, along with their stimulus-responsive behavior, drug-loading efficiency, and surface functionalization. The cytotoxic effects on glioblastoma cell lines, biodistribution, and biosafety profiles are also rigorously assessed, along with in vitro and in vivo research. There is also discussion of toxicity issues, scalable synthesis, and limited clinical translation. This review highlights the transformative potential of GQD-integrated nanocomposites as a next-generation therapeutic platform for effectively managing GBM.
Indexed as
Identifiers
40781177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.